Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
المؤلفون المشاركون
Dvir, Addie
Soussan-Gutman, Lior
Stemmer, Salomon M.
Epelbaum, Ron
Shacham-Shmueli, Einat
Klein, Baruch
Agbarya, Abed
Brenner, Baruch
Brenner, Ronen
Gez, Eliahu
Golan, Talia
Purim, Ofer
Temper, Mark
Tepper, Ella
Voss, Andreas
Russell, Kenneth
Geva, Ravit
Hubert, Ayala
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-05-28
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
This multicenter cohort study assessed the impact of molecular profiling (MP) on advanced pancreaticobiliary cancer (PBC).
The study included 30 patients treated with MP-guided therapy after failing ≥1 therapy for advanced PBC.
Treatment was considered as having benefit for the patient if the ratio between the longest progression-free survival (PFS) on MP-guided therapy and the PFS on the last therapy before MP was ≥1.3.
The null hypothesis was that ≤15% of patients gain such benefit.
Overall, ≥1 actionable (i.e., predictive of response to specific therapies) biomarker was identified/patient.
Immunohistochemistry (the most commonly used method for guiding treatment decisions) identified 1–6 (median: 4) actionable biomarkers per patient.
After MP, patients received 1–4 (median: 1) regimens/patient (most commonly, FOLFIRI/XELIRI).
In a decision-impact analysis, of the 27 patients for whom treatment decisions before MP were available, 74.1% experienced a treatment decision change in the first line after MP.
Twenty-four patients were evaluable for clinical outcome analysis; in 37.5%, the PFS ratio was ≥1.3.
In one-sided exact binomial test versus the null hypothesis, P = 0.0015; therefore, the null hypothesis was rejected.
In conclusion, our analysis demonstrated the feasibility, clinical decision impact, and potential clinical benefits of MP-guided therapy in advanced PBC.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Epelbaum, Ron& Shacham-Shmueli, Einat& Klein, Baruch& Agbarya, Abed& Brenner, Baruch& Brenner, Ronen…[et al.]. 2015. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1056370
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Epelbaum, Ron…[et al.]. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1056370
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Epelbaum, Ron& Shacham-Shmueli, Einat& Klein, Baruch& Agbarya, Abed& Brenner, Baruch& Brenner, Ronen…[et al.]. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1056370
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1056370
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر